Stockscreener 앱 받기
3.3985
5.72%
-0.2115
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials - Yahoo Finance
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Treatment and Melanoma - Minichart
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline - TipRanks
Perspective Therapeutics (CATX) updates radiopharmaceutical oncology pipeline presentation - Stock Titan
Millennium reports 4.89M shares (4.3%) in Perspective Therapeutics | CATX SEC FilingForm SCHEDULE 13G - Stock Titan
CATX: Analyst Engages with Management in Virtual Discussion - GuruFocus
Perspective Therapeutics, Inc. Actuals & Estimates (AMEX:CATX) - TradingView
Perspective Therapeutics, Inc. Actuals & Estimates (TRADEGATE:AAJ0) - TradingView
Enterprise value to revenue forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Price to earnings forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
CATX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Perspective Therapeutics Inc (CATX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Perspective Therapeutics Inc (CATX) Institutional Confidence - TradingKey
Perspective Therapeutics Inc (CATX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Perspective Therapeutics Inc (CATX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Perspective Therapeutics Inc (CATX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Perspective Therapeutics Inc (CATX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Investor ConfidenceEarnings Revision Downgrade - dars.gov.et
Perspective Therapeutics Inc - TradingKey
Perspective Therapeutics Inc (CATX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail
Enliven Therapeutics Surges on Promising Leukemia Drug Trial ResultsEarnings Outlook Update - newsline.com
Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort - Moomoo
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Clinical ProgressForward Guidance Trends - newsline.com
Perspective Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Radioligand Therapy Market is Expected to Grow Rapidly by 2036, Estimates DelveInsight - openPR.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial - Yahoo Finance
Perspective Therapeutics (CATX) Initiates Meningioma Patient Stu - GuruFocus
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - The Manila Times
Targeted alpha therapy trial doses first patient for common brain tumor - Stock Titan
Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer - The Globe and Mail
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities - The Globe and Mail
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective updates corporate presentation detailing 212Pb radiopharmaceutical pipeline and regional production strategy - TradingView
Perspective Therapeutics (NYSE: CATX) outlines 212Pb cancer pipeline update - Stock Titan
H.C. Wainwright Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Vivos Therapeutics (VVOS) Gains 4.5% as Stock Tests Key Resistance at $0.73Growth Stock Picks - thelegaladvocate.com
Perspective Therapeutics (CATX) Slides 2.72% as Stock Tests Key Support LevelsBollinger Squeeze - newsline.com
Edgewise Therapeutics Inc. (EWTW) Q1 2026 Earnings: Narrower Losses Bolster Investor SentimentRevenue Estimate Trend - thelegaladvocate.com
Cullinan Therapeutics (CGEM) Retreats 1% as Stock Approaches Support ZoneLarge Cap Trends - thelegaladvocate.com
Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting - Yahoo Finance
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEPS Surprise History - thelegaladvocate.com
Fluidra Appoints Juan Graham as Chief Financial Officer - hrtoday.in
Aprea Therapeutics (APRE) Edges Higher Amid Light Trading; Key Resistance at $0.99 in FocusOBV Divergence - thelegaladvocate.com
Perspective Therapeutics, Inc. 8-K Filing Details for May 27, 2026: Company Information and SEC Compliance - Minichart
Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026 - Yahoo Finance
CATX Q1 2026 Earnings: Narrower Loss Fails to Lift Pre-Revenue BiotechMargin Guidance - newsline.com
CATXPerspective Therapeutics Inc Stock Price and Quote - Finviz
Perspective Therapeutics shareholders approve directors and governance items - TipRanks
Shareholders of Perspective Therapeutics (NYSE: CATX) back board, auditor - Stock Titan
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: Loss Narrows Sharply, Stock Gains 2.84%Profitability Analysis - thelegaladvocate.com
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $8 to $15 - Moomoo
Perspective Therapeutics (CATX) Gains 2.84% as Stock Nears Key Resistance at $4.18High Yield Stocks - newsline.com
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: EPS Beat by 17% as Pre‑Revenue Biotech Advances Radiopharmaceutical PipelineEarnings Per Share - newsline.com
Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX) - The Globe and Mail
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Perspective Therapeutics Presents Positive Clinical Data for [212Pb] Radiopharmaceuticals in Melanoma, Neuroendocrine, and Solid Tumors at ASCO 2026 - Minichart
Perspective Therapeutics (NYSE: CATX) highlights new 212Pb trial data at 2026 ASCO - Stock Titan
0.43%
0.38%
자본화:
|
볼륨(24시간):